Evotec SE (EVO) Receives Grants to Advance Tuberculosis Treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Evotec Receives Grants to Advance Tuberculosis Treatment
April 30, 2026 3:20 AM EDTGrants support discovery and development of novel drug candidates and evaluation and prioritization of advanced drug regimens for clinical testing
New funding from the Gates Foundation extends Evotec's commitment to create more effective tuberculosis treatment regimens
HAMBURG, GERMANY / ACCESS Newswire / April 30, 2026 / Evotec SE (NASDAQ: EVO)(Frankfurt Prime Standard:EVT) today announced that it has received two grants from the Gates Foundation for drug discovery and translation in tuberculosis (TB), following four earlier TB grants from the... More
